DB18944InvestigationalProtein Based Therapies
Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell...
- Also known as
- Anti-cd20/cd3 monoclonal antibody xmab13676
- Code names
- XENP13676 · XMAB-13676
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Plamotamab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account